Abstral filed in US for breakthrough cancer pain
This article was originally published in Scrip
Executive Summary
Orexo AB and ProStrakan have filed an NDA with the US FDA for Abstral (fentanyl citrate), for the treatment of breakthrough cancer pain in opioid-tolerant patients.